Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis

Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry

(2020) Lillian M Smyth et al.   Cancer Discovery

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

(2020) Lillian M Smyth et al.   CLINICAL CANCER RESEARCH

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

(2019) Neil Vasan et al.   SCIENCE

Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components

(2018) Chieko Mishima et al.   AMERICAN JOURNAL OF PATHOLOGY

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus

(2018) Claudia Omarini et al.   Biomed Research International

Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers

(2018) Federico De Marchi et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

AKT Inhibition in Solid Tumors With AKT1 Mutations

(2017) David M. Hyman et al.   JOURNAL OF CLINICAL ONCOLOGY

AKT1 low Quiescent Cancer Cells Promote Solid Tumor Growth

(2017) Cleidson P. Alves et al.   MOLECULAR CANCER THERAPEUTICS

Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence

(2017) Ümmügülsüm Yesilöz et al.   NEURO-ONCOLOGY

Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer

(2017) Carmela De Marco et al.   PLoS One

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients

(2017) Elza C. de Bruin et al.   PLoS One

Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity

(2017) S. Oeck et al.   Scientific Reports

AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

(2016) Marion Rudolph et al.   BMC CANCER

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

(2016) Kenji Tamura et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis

(2016) Maria L. Mancini et al.   Oncotarget

Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?

(2015) A. C. Yeh et al.   CANCER RESEARCH

AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants

(2015) J. F. Hechtman et al.   MOLECULAR CANCER RESEARCH

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

(2015) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

Mutant AKT1-E17K is oncogenic in lung epithelial cells

(2015) Carmela De Marco et al.   Oncotarget

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

(2015) Yi Yu et al.   PLoS One

RNA helicase DDX21 coordinates transcription and ribosomal RNA processing

(2014) Eliezer Calo et al.   NATURE

Akt SUMOylation Regulates Cell Proliferation and Tumorigenesis

(2013) R. Li et al.   CANCER RESEARCH

Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas

(2013) D. Garcia-Carracedo et al.   CLINICAL CANCER RESEARCH

PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System

(2013) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

PIK3CA-AKT pathway mutations in micropapillary breast carcinoma

(2013) Ellen Flatley et al.   HUMAN PATHOLOGY

AKT1 Gene Mutation Levels Are Correlated with the Type of Dermatologic Lesions in Patients with Proteus Syndrome

(2013) Marjorie J. Lindhurst et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain

(2013) Ambuj Kumar et al.   PLoS One

The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis

(2012) Chia-Hsin Chan et al.   CELL

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

(2012) N. Rekhtman et al.   CLINICAL CANCER RESEARCH

Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells

(2012) Bodour Salhia et al.   HUMAN MUTATION

Ubiquitin-dependent Regulation of Phospho-AKT Dynamics by the Ubiquitin E3 Ligase, NEDD4-1, in the Insulin-like Growth Factor-1 Response

(2012) Chuan-Dong Fan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression

(2011) Kevin Kalinsky et al.   BREAST CANCER RESEARCH AND TREATMENT

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks

(2011) Michael Fraser et al.   CELL CYCLE

Intraductal papillary mucinous neoplasm

(2011) Chanjuan Shi et al.   HUMAN PATHOLOGY

A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome

(2011) Marjorie J. Lindhurst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Asymmetric cancer cell division regulated by AKT

(2011) I. Dey-Guha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Akt1 in murine chondrocytes controls cartilage calcification during endochondral ossification under physiologic and pathologic conditions

(2010) Atsushi Fukai et al.   ARTHRITIS AND RHEUMATISM

E17K substitution in AKT1 in prostate cancer

(2010) J L Boormans et al.   BRITISH JOURNAL OF CANCER

Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung

(2010) Donatella Malanga et al.   CELL CYCLE

Rarity ofAKT1andAKT3E17K mutations in squamous cell carcinoma of lung

(2010) Hongdo Do et al.   CELL CYCLE

Regulation of Akt signaling activation by ubiquitination

(2010) Wei-Lei Yang et al.   CELL CYCLE

Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations

(2010) J Lauring et al.   ONCOGENE

Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells

(2010) G Guo et al.   ONCOGENE

Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas

(2009) Hyeon Seok Eom et al.   ACTA ONCOLOGICA

4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors

(2009) Upul Bandarage et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

(2009) Jennifer Dunlap et al.   BREAST CANCER RESEARCH AND TREATMENT

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

(2009) K Shoji et al.   BRITISH JOURNAL OF CANCER

AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma

(2009) Dorit E. Zilberman et al.   CANCER GENETICS AND CYTOGENETICS

PIKKing on PKB: regulation of PKB activity by phosphorylation

(2009) Lana Bozulic et al.   CURRENT OPINION IN CELL BIOLOGY

TTC3 Ubiquitination Terminates Akt-ivation

(2009) Alex Toker   DEVELOPMENTAL CELL

The E3 Ligase TTC3 Facilitates Ubiquitination and Degradation of Phosphorylated Akt

(2009) Futoshi Suizu et al.   DEVELOPMENTAL CELL

High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast

(2009) Megan L Troxell et al.   MODERN PATHOLOGY

Ubiquitylation in innate and adaptive immunity

(2009) Vijay G. Bhoj et al.   NATURE

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

(2009) J M Askham et al.   ONCOGENE

The E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation

(2009) W.-L. Yang et al.   SCIENCE

Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain†

(2008) Kyle E. Landgraf et al.   BIOCHEMISTRY

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

(2008) M S Kim et al.   BRITISH JOURNAL OF CANCER

Akt Determines Replicative Senescence and Oxidative or Oncogenic Premature Senescence and Sensitizes Cells to Oxidative Apoptosis

(2008) Veronique Nogueira et al.   CANCER CELL

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

An activating mutation inAKT1in human prostate cancer

(2008) Joost L. Boormans et al.   INTERNATIONAL JOURNAL OF CANCER

The role of PTEN signaling perturbations in cancer and in targeted therapy

(2008) M Keniry et al.   ONCOGENE

AKT1 E17K in human solid tumours

(2008) F E Bleeker et al.   ONCOGENE

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

(2008) C Garcia-Echeverria et al.   ONCOGENE